Donor T lymphocyte nuclear DNA

Donor T lymphocyte nuclear DNA refers to the genomic material within the nuclei of T cells provided by a donor during allogeneic hematopoietic stem cell transplantation (HSCT), donor lymphocyte infusion (DLI), or blood transfusion. In clinical pharmacology, this DNA is the primary molecular target for post-transplant cyclophosphamide (PT-Cy), which selectively eliminates alloreactive donor T cells by inducing lethal DNA cross-links during their rapid expansion phase to prevent Graft-versus-Host Disease (GvHD) (Luznik et al., 2008). It is also the target of pathogen inactivation technologies, such as amotosalen and ultraviolet light, which cross-link donor DNA to prevent transfusion-associated GvHD (McCullough et al., 2004). Furthermore, the donor T lymphocyte genome serves as the substrate for genetic engineering in advanced cellular therapies, including the insertion of chimeric antigen receptors (CARs) or suicide genes like herpes simplex virus thymidine kinase (HSV-TK) (Bonini et al., 1997). Monitoring this DNA through lineage-specific chimerism analysis is essential for assessing donor cell engraftment and predicting transplant outcomes (Lion, 2014). The integrity and presence of this DNA are critical for the long-term success of the graft-versus-leukemia effect, while its over-activity can lead to severe systemic inflammation.

Other names

Donor T-cell DNADonor T-lymphocyte genomeDonor-derived T-cell DNA

DNA cross-linking and alkylation (Cyclophosphamide, Busulfan, Amotosalen); DNA synthesis inhibition (Fludarabine); DNA chain termination (Ganciclovir in suicide gene therapy)